Pharmacology of Restless Legs Syndrome (RLS), Volume 84, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field on essential topics, with this volume presenting chapters on Targeting the adenosinergic system in Restless Legs Syndrome, Assessing iron uptake mechanisms in the brain: impact of gender and genotype, Pharmacological treatments of RLS in augmentation, C. elegans and its applicability to studies on RLS, The neurophysiology of hyperarousal in RLS: hints for a role of glutamate/GABA, Treatment management and options in RLS patients, Pharmacological responsiveness of Periodic Legs Movements during Sleep, and more.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. xi 6. Preface - p. xv 7. Section I: Pathophysiology - p. xvi 8. Chapter One: Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport - p. xvi 9. Chapter Two: D3 receptor agonist efficacy in restless legs syndrome - p. 19 10. Chapter Three: The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndrome - p. 35 11. Chapter Four: D3 and D1 receptors: The Yin and Yang in the treatment of restless legs syndrome with dopaminergics - p. 78 12. Chapter Five: The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA - p. 100 13. Section II: Disease models/genetics - p. 119 14. Chapter Six: Iron uptake at the blood-brain barrier is influenced by sex and genotype - p. 119 15. Chapter Seven: Caenorhabditis elegans and its applicability to studies on restless legs syndrome - p. 145 16. Chapter Eight: Role of MEIS1 in restless legs syndrome: From GWAS to functional studies in mice - p. 174 17. Section III: Treatments and treatment complications - p. 184 18. Chapter Nine: Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome - p. 184 19. Chapter Ten: Idiopathic restless legs syndrome treatment: Progress and pitfalls? - p. 205 20. Chapter Eleven: Treatment of pediatric restless legs syndrome - p. 235 21. Chapter Twelve: Pharmacological treatments of augmentation in restless legs syndrome patients - p. 253
Pharmacology of Restless Legs Syndrome (RLS), Volume 84, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field on essential topics, with this volume presenting chapters on Targeting the adenosinergic system in Restless Legs Syndrome, Assessing iron uptake mechanisms in the brain: impact of gender and genotype, Pharmacological treatments of RLS in augmentation, C. elegans and its applicability to studies on RLS, The neurophysiology of hyperarousal in RLS: hints for a role of glutamate/GABA, Treatment management and options in RLS patients, Pharmacological responsiveness of Periodic Legs Movements during Sleep, and more.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. xi 6. Preface - p. xv 7. Section I: Pathophysiology - p. xvi 8. Chapter One: Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport - p. xvi 9. Chapter Two: D3 receptor agonist efficacy in restless legs syndrome - p. 19 10. Chapter Three: The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndrome - p. 35 11. Chapter Four: D3 and D1 receptors: The Yin and Yang in the treatment of restless legs syndrome with dopaminergics - p. 78 12. Chapter Five: The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA - p. 100 13. Section II: Disease models/genetics - p. 119 14. Chapter Six: Iron uptake at the blood-brain barrier is influenced by sex and genotype - p. 119 15. Chapter Seven: Caenorhabditis elegans and its applicability to studies on restless legs syndrome - p. 145 16. Chapter Eight: Role of MEIS1 in restless legs syndrome: From GWAS to functional studies in mice - p. 174 17. Section III: Treatments and treatment complications - p. 184 18. Chapter Nine: Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome - p. 184 19. Chapter Ten: Idiopathic restless legs syndrome treatment: Progress and pitfalls? - p. 205 20. Chapter Eleven: Treatment of pediatric restless legs syndrome - p. 235 21. Chapter Twelve: Pharmacological treatments of augmentation in restless legs syndrome patients - p. 253
